Luye Pharma Group Stock Performance
| LYPHF Stock | USD 0.34 0.00 0.00% |
Luye Pharma has a performance score of 9 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.0654, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Luye Pharma are expected to decrease at a much lower rate. During the bear market, Luye Pharma is likely to outperform the market. Luye Pharma Group right now secures a risk of 1.21%. Please verify Luye Pharma Group standard deviation, as well as the relationship between the maximum drawdown and day median price , to decide if Luye Pharma Group will be following its current price movements.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Luye Pharma Group are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak technical indicators, Luye Pharma may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
| Begin Period Cash Flow | 3.9 B | |
| Total Cashflows From Investing Activities | -3.4 B |
Luye |
Luye Pharma Relative Risk vs. Return Landscape
If you would invest 31.00 in Luye Pharma Group on August 27, 2024 and sell it today you would earn a total of 3.00 from holding Luye Pharma Group or generate 9.68% return on investment over 90 days. Luye Pharma Group is currently producing 0.1512% returns and takes up 1.2097% volatility of returns over 90 trading days. Put another way, 10% of traded pink sheets are less volatile than Luye, and 97% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Luye Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Luye Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Luye Pharma Group, and traders can use it to determine the average amount a Luye Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.125
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LYPHF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.21 actual daily | 10 90% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Luye Pharma is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Luye Pharma by adding it to a well-diversified portfolio.
Luye Pharma Fundamentals Growth
Luye Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Luye Pharma, and Luye Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Luye Pink Sheet performance.
| Return On Equity | -0.0261 | |||
| Return On Asset | 0.0081 | |||
| Profit Margin | (0.04) % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 2.08 B | |||
| Shares Outstanding | 3.55 B | |||
| Price To Book | 2.17 X | |||
| Price To Sales | 0.47 X | |||
| Revenue | 5.2 B | |||
| EBITDA | 324.9 M | |||
| Total Debt | 4.21 B | |||
| Debt To Equity | 1.15 % | |||
| Book Value Per Share | 2.54 X | |||
| Cash Flow From Operations | 182.37 M | |||
| Earnings Per Share | 0.03 X | |||
| Total Asset | 22.58 B | |||
About Luye Pharma Performance
By analyzing Luye Pharma's fundamental ratios, stakeholders can gain valuable insights into Luye Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Luye Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Luye Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Luye Pharma Group Ltd. develops, produces, markets, and sells pharmaceutical products worldwide. The company was founded in 1994 and is headquartered in Yantai, the Peoples Republic of China. Luye Pharma is traded on OTC Exchange in the United States.Things to note about Luye Pharma Group performance evaluation
Checking the ongoing alerts about Luye Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Luye Pharma Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Luye Pharma Group has some characteristics of a very speculative penny stock | |
| Luye Pharma Group has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 5.2 B. Net Loss for the year was (134.39 M) with profit before overhead, payroll, taxes, and interest of 3.4 B. | |
| About 35.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Luye Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Luye Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Luye Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Luye Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Luye Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Luye Pharma's pink sheet. These opinions can provide insight into Luye Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Luye Pink Sheet analysis
When running Luye Pharma's price analysis, check to measure Luye Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Luye Pharma is operating at the current time. Most of Luye Pharma's value examination focuses on studying past and present price action to predict the probability of Luye Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Luye Pharma's price. Additionally, you may evaluate how the addition of Luye Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |